AbbVie Seeks Approval of Upadacitinib for Ulcerative Colitis
The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.
Colorectal Disorders
Guidance Updated for Managing C difficile Infection in Adults
Fidaxomicin suggested instead of vancomycin for initial Clostridioides difficile infection episode, recurrent CDI episodes
Upadacitinib Meets Endpoints in Ulcerative Colitis Maintenance Trial
A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.
Diets Compared for Mild to Moderate Crohn Disease in Adults
Rate of symptomatic remission at week 6 similar for Mediterranean diet, specific carbohydrate diet in randomized trial
Zeposia Approved for Moderately to Severely Active Ulcerative Colitis
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
ACG Issues Guidelines for C. Diff Management in Adults
Authors recommend against probiotics for prevention of CDI; in those with CDI recurrence, FMT recommended to prevent further recurrence
Many Patients Prefer Stool-Based Colorectal Cancer Screening Tests
Multitarget stool DNA test, fecal immunochemical test, or guaiac-based fecal occult blood test preferred over colonoscopy
COVID-19 Vaccination of IBD Patients: Do Biologics Impact Serological Responses?
Patients with IBD were compared to control groups without IBD, which included 14 completely vaccinated healthcare workers and 29 vaccinated healthy volunteers.
Infliximab May Impede Serologic Response to SARS-CoV-2
Concomitant immunomodulator use further blunted antibody responses to SARS-CoV-2 among infliximab-treated IBD patients
Clinical Remission Reported With Mirikizumab in Ulcerative Colitis Trial
LUCENT-1 is a 12-week, double-blind, placebo-controlled induction study evaluating mirikizumab in over 1100 UC patients who had an inadequate response to, loss of response, or were intolerant to conventional or biologic therapy for UC.
